Page last updated: 2024-11-13

hs 6

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

HS 6: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135524616
MeSH IDM0043950

Synonyms (9)

Synonym
hs 6 (pharmaceutical)
pyridinium, 1-(((3-(aminocarbonyl)pyridinio)methoxy)methyl)-2-((hydroxyimino)methyl)-, 2cl
1-((3-(aminocarbonyl)pyridinio)methoxymethyl)-2-((hydroxyimino)methyl)pyridinium dichloride
pyridinium, 3'-carbamoyl-2-formyl-1,1'-(oxydimethylene)di-, dichloride, 2-oxime
hs-6
1-(((3-(aminocarbonyl)pyridinio)methoxy)methyl)-2-((hydroxyimino)methyl)pyridinium dichloride
hs 6
3'-carbamoyl-2-formyl-1,1'-(oxydimethylene)dipyridinium dichloride 2-oxime
22625-23-6

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Maximum protection, as determined by a shift of the LD50 for the two OP agents, was observed with the cholinolytic benactyzine."( Actions and interactions of cholinolytics and cholinesterase reactivators in the treatment of acute organophosphorus toxicity.
Asthana, SN; Batra, BS; Chowdhri, BL; Das Gupta, S; Ghosh, AK, 1991
)
0.28
"Cyclosarin (GF-agent; O-cyclohexylmethylfluorophosphonate) belongs to highly toxic organophosphorus compounds."( Signs of cyclosarin-induced neurotoxicity and its pharmacological treatment with quaternary pyridinium-oximes reactivators.
Bartosova, L; Krejcova-Kunesova, G; Kuca, K, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (75.00)18.7374
1990's1 (5.00)18.2507
2000's3 (15.00)29.6817
2010's1 (5.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]